secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001477932-23-005506
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus closes $5.75M public offering and uplists to Nasdaq
------------------------------------------------------------

- Closed underwritten public offering of 1,437,500 shares at $4.00/share; gross proceeds $5.75M.
- Underwriter fully exercised over-allotment option for 187,500 additional shares.
- Common stock began trading on Nasdaq Capital Market on July 20, 2023 under symbol BGLC.
- Underwriter issued warrants for 115,000 shares at $4.40/share, exercisable for 5 years.
- Lock-up agreements with officers, directors, and certain shareholders for 180 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/0001477932-23-005506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-005506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer